JPWO2023125619A5 - - Google Patents
Info
- Publication number
- JPWO2023125619A5 JPWO2023125619A5 JP2024538092A JP2024538092A JPWO2023125619A5 JP WO2023125619 A5 JPWO2023125619 A5 JP WO2023125619A5 JP 2024538092 A JP2024538092 A JP 2024538092A JP 2024538092 A JP2024538092 A JP 2024538092A JP WO2023125619 A5 JPWO2023125619 A5 JP WO2023125619A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- ror1
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111623091.0 | 2021-12-28 | ||
| CN202111623091 | 2021-12-28 | ||
| CN202210230033.X | 2022-03-10 | ||
| CN202210230033 | 2022-03-10 | ||
| PCT/CN2022/142644 WO2023125619A1 (zh) | 2021-12-28 | 2022-12-28 | 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503493A JP2025503493A (ja) | 2025-02-04 |
| JPWO2023125619A5 true JPWO2023125619A5 (https=) | 2026-01-13 |
| JP2025503493A5 JP2025503493A5 (https=) | 2026-01-13 |
Family
ID=86997955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538092A Pending JP2025503493A (ja) | 2021-12-28 | 2022-12-28 | 抗ｒｏｒ１抗体と抗ｒｏｒ１抗体薬物複合体及びその医薬的使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250121081A1 (https=) |
| EP (1) | EP4458850A4 (https=) |
| JP (1) | JP2025503493A (https=) |
| KR (1) | KR20240125944A (https=) |
| CN (1) | CN118302448A (https=) |
| CA (1) | CA3242972A1 (https=) |
| TW (1) | TW202330619A (https=) |
| WO (1) | WO2023125619A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN118496347B (zh) * | 2024-05-30 | 2024-10-25 | 北京航空航天大学杭州创新研究院 | 一种用于抗体寡核苷酸偶联的方法 |
| WO2026077394A1 (zh) * | 2024-10-10 | 2026-04-16 | 杭州博之锐生物制药有限公司 | 一种抗ror1抗体-药物偶联物的药物组合物及其应用 |
| WO2026077395A1 (zh) * | 2024-10-10 | 2026-04-16 | 杭州博之锐生物制药有限公司 | 抗ror1抗体药物-偶联物的联合用药 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| JP6865688B2 (ja) * | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| WO2018119314A1 (en) * | 2016-12-22 | 2018-06-28 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| WO2021057822A1 (en) * | 2019-09-27 | 2021-04-01 | Immuther Pharmtech (Shanghai) Co., Ltd. | Anti-ror1 antibodies and preparation method and uses thereof |
| EP4241789A4 (en) * | 2020-12-08 | 2025-04-02 | Nona Biosciences (Shanghai) Co., Ltd. | Protein-drug conjugate and site-specific conjugation method |
-
2022
- 2022-12-28 CN CN202280078230.2A patent/CN118302448A/zh active Pending
- 2022-12-28 CA CA3242972A patent/CA3242972A1/en active Pending
- 2022-12-28 EP EP22914871.3A patent/EP4458850A4/en active Pending
- 2022-12-28 WO PCT/CN2022/142644 patent/WO2023125619A1/zh not_active Ceased
- 2022-12-28 KR KR1020247023063A patent/KR20240125944A/ko active Pending
- 2022-12-28 US US18/724,604 patent/US20250121081A1/en active Pending
- 2022-12-28 JP JP2024538092A patent/JP2025503493A/ja active Pending
- 2022-12-28 TW TW111150439A patent/TW202330619A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7571805B2 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| JP7467526B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2024059609A5 (https=) | ||
| JP2019536740A5 (https=) | ||
| JP2019532056A5 (https=) | ||
| TWI726217B (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| JPWO2021147993A5 (https=) | ||
| CN115335400A (zh) | 结合整合素avb8的抗体及其用途 | |
| JP2018528759A5 (https=) | ||
| KR20260005325A (ko) | 항-ptk7 항체 및 그의 용도 | |
| EP3439692A2 (en) | Plectin-1 binding antibodies and uses thereof | |
| JPWO2022087243A5 (https=) | ||
| WO2023143319A1 (zh) | 抗体药物偶联物、药物组合物及用途 | |
| EP3638309A1 (en) | Antibody drug conjugates that bind lgr5 | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| JP2004536578A (ja) | 腫瘍ターゲティング用の抗−ｍｕｃ−１単鎖抗体 | |
| JPWO2023125619A5 (https=) | ||
| JPWO2019212965A5 (https=) | ||
| WO2025036480A1 (zh) | 化合物以及含有该化合物的抗体偶联药物 | |
| JPWO2022147532A5 (https=) | ||
| CN115975030B (zh) | 抗cd39抗体-药物偶联物及其用途 | |
| JPWO2023083846A5 (https=) |